End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
44.66 CNY | +2.83% |
|
+3.36% | -21.66% |
Jul. 02 | Autobio Diagnostics Gets Registration Certificates for 14 Devices | MT |
May. 21 | Autobio Diagnostics' Unit Gets Nod for Two Products | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 58% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's enterprise value to sales, at 4.85 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.66% | 3.47B | C | ||
-6.61% | 12.07B | B+ | ||
+91.77% | 8.2B | C | ||
-18.38% | 6.59B | B- | ||
+9.13% | 5.89B | B | ||
+5.36% | 2.52B | - | - | |
+41.27% | 2.48B | C | ||
+17.72% | 2.3B | B- | ||
-18.43% | 1.58B | D+ | ||
-9.77% | 1.36B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603658 Stock
- Ratings Autobio Diagnostics Co., Ltd.